Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors

Do you have Recurrent endometrial cancer,Recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed during or after standard treatments? If so, you may be able to take part in a research study looking at the safety of giving a treatment of test drug IMGN151-1001 to patients with these types of cancer

Have you been diagnosed with relapsed or refractory light chain amyloidosis? If so, you may be able to take part in a research study looking at the safety and tolerability of giving Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone to patients with relapsed or refractory light chain amyloidosis.

Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

Do you have bladder cancer that has spread to nearby tissue or other parts of the body? You may be able to participate in a research study to find out if the investigational drug disitamab vedotin alone or with pembrolizumab works to treat bladder cancer.

Do you have Stage III or Stage IV Non-Small Cell Lung Cancer? Do you have a KRAS G12C mutation or are you interested in testing for this? If so, you may be able to participate in a study to see if adding a new medicine is more effective at controlling your cancer than the usual treatments.

Have you been diagnosed with pancreatic adenocarcinoma? If so, you may be a good fit to help us learn if combination treatment with specific drugs may stimulate the body's immune system against cancer cells.

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

This study aims to understand how a person's race and where they live affect the quality of breast cancer care they receive. We invite Black and/or African American breast cancer patients and survivors from specific areas of North Carolina to participate in a virtual focus group. The purpose of this focus group is to get your feedback about maps and other tools our team has created to show how breast cancer care quality varies around the state and by race. We also want to hear your experiences seeking care in your area, and your ideas about possible reasons behind the patterns in your area.